LifeStance Health Group (LFST) vs GeneDx (WGS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
LifeStance Health Group (LFST) has outperformed GeneDx (WGS) over the past year, gaining 119.0% versus a loss of 43.3%. Over five years, LFST leads with a +5.3% price change compared with -73.3% for WGS. LifeStance Health Group is the larger company by market cap ($4.58 billion vs $2.02 billion), about 2.3 times the size.
On valuation, LifeStance Health Group trades at a lower forward P/E (28.0x vs 56.5x for GeneDx).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LFST | WGS |
|---|---|---|
| Share price | $12.06 | $67.73 |
| Market cap | $4.58B | $2.02B |
| 1-day change | -0.41% | -1.17% |
| YTD return | +72.02% | -47.31% |
| 1-year return | +118.99% | -43.25% |
| 5-year return | +5.30% | -73.34% |
| P/E ratio (TTM) | 92.77 | — |
| Forward P/E | 28.00 | 56.51 |
| EPS (TTM) | $0.13 | $-3.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.42B | — |
| Revenue growth (YoY) | +13.85% | — |
| Net income (latest FY) | $9.66M | — |
| Operating margin | 1.70% | — |
| Net margin | 0.68% | — |
| 52-week high | $13.56 | $170.87 |
| 52-week low | $4.77 | $32.21 |
| Distance from 52-week high | -11.06% | -60.36% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +19.40% | +38.05% |
| Average volume | 4.36M | 728.47K |
| Shares outstanding | 380.15M | 29.82M |
| Employees | 8,542 | 1,300 |
| Sector | Health Care | Health Care |
| Industry | Medical/Nursing Services | Medical/Nursing Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LifeStance Health Group is about 2.3 times larger than GeneDx by market value ($4.58B vs $2.02B).
- LFST has outperformed WGS by 162.2 percentage points over the past year.
About LifeStance Health Group
LFST stock →LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
Health Care · Medical/Nursing Services · 8,542 employees
About GeneDx
WGS stock →GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Health Care · Medical/Nursing Services · 1,300 employees
LFST vs WGS FAQ
Which is bigger, LifeStance Health Group or GeneDx?
LifeStance Health Group (LFST) is larger, with a market capitalization of $4.58B compared with $2.02B for GeneDx (WGS).
Which stock has performed better over the past year, LFST or WGS?
LFST returned +118.99% over the past 12 months, compared with -43.25% for WGS (price return, excluding dividends). Past performance does not predict future results.
Are LifeStance Health Group and GeneDx in the same industry?
Yes. Both are classified in the Medical/Nursing Services industry within the Health Care sector.